108 related articles for article (PubMed ID: 6319895)
1. Quaternary derivatives of narcotic antagonists: stereochemical requirements at the chiral nitrogen for in vitro and in vivo activity.
Bianchetti A; Nisato D; Sacilotto R; Dragonetti M; Picerno N; Tarantino A; Manara L; Angel LM; Simon EJ
Life Sci; 1983; 33 Suppl 1():415-8. PubMed ID: 6319895
[TBL] [Abstract][Full Text] [Related]
2. Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists.
Valentino RJ; Katz JL; Medzihradsky F; Woods JH
Life Sci; 1983 Jun; 32(25):2887-96. PubMed ID: 6304445
[TBL] [Abstract][Full Text] [Related]
3. Relative ability of N-methyl nalorphine and N-methyl levallorphan to prevent antinociception and intestinal transit inhibition in morphine treated rats.
Notarnicola A; Landi M; Bianchi G; Tavani A
Life Sci; 1983; 33 Suppl 1():481-4. PubMed ID: 6664229
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
5. N-cubylmethyl substituted morphinoids as novel narcotic antagonists.
Cheng CY; Hsin LW; Lin YP; Tao PL; Jong TT
Bioorg Med Chem; 1996 Jan; 4(1):73-80. PubMed ID: 8689242
[TBL] [Abstract][Full Text] [Related]
6. 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers.
Schmidhammer H; Leander JD; Mayer-Valkanover K; Nussbaumer C; Schmidt C; Schoepp DD; Schratz A; Walla-Kugler M
Prog Clin Biol Res; 1990; 328():41-4. PubMed ID: 2154800
[No Abstract] [Full Text] [Related]
7. Fluorescent probes for opioid receptors.
Kolb VM; Koman A; Terenius L
Life Sci; 1983; 33 Suppl 1():423-6. PubMed ID: 6319896
[TBL] [Abstract][Full Text] [Related]
8. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
9. The peripheral narcotic antagonist N-allyl levallorphan-bromide (CM 32191) selectively prevents morphine antipropulsive action and buprenorphine in-vivo binding in the rat intestine.
Bianchi G; Fiocchi R; Peracchia F; Petrillo P; Tavani A; Manara L
J Pharm Pharmacol; 1984 May; 36(5):326-30. PubMed ID: 6145770
[TBL] [Abstract][Full Text] [Related]
10. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.
Culpepper-Morgan JA; Holt PR; LaRoche D; Kreek MJ
Life Sci; 1995; 56(14):1187-92. PubMed ID: 7475895
[TBL] [Abstract][Full Text] [Related]
11. Affinities of opiate agonists and antagonists for the enkephalin receptors of rat brain.
Wong DT; Horng JS
Res Commun Chem Pathol Pharmacol; 1977 Apr; 16(4):749-52. PubMed ID: 193169
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gastrointestinal transit by morphine and FK 33-824 in the rat and comparative narcotic antagonist properties of naloxone and its N-methyl quaternary analog.
Manara L; Bianchi G; Fiocchi R; Notarnicola A; Peracchia F; Tavani A
Life Sci; 1982 Sep 20-27; 31(12-13):1271-4. PubMed ID: 6183550
[TBL] [Abstract][Full Text] [Related]
13. Influence of spatial orientation of the C-6-OH group in ring C of morphine derivatives on opioid activity.
Friedmann T; Tóth Z; Hosztafi S; Simon CS; Makleit S; Fürst S
Arch Int Pharmacodyn Ther; 1994; 328(1):16-25. PubMed ID: 7893188
[TBL] [Abstract][Full Text] [Related]
14. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
Takemori AE; Larson DL; Portoghese PS
Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological actions of levallorphan allyl bromide (CM 32191), a new peripheral narcotic antagonist.
Bianchetti A; Giudice A; Picerno N; Carminati P
Life Sci; 1982 Nov 15-22; 31(20-21):2261-4. PubMed ID: 6186879
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist opioid activity of axial and equatorial conformations of S-methyl- and S-allyl-morphinans.
Lemaire S; Belleau B; Jolicoeur FB
Eur J Pharmacol; 1994 Jun; 258(1-2):111-8. PubMed ID: 7925589
[TBL] [Abstract][Full Text] [Related]
17. Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity.
Bianchi G; Fiocchi R; Tavani A; Manara L
Life Sci; 1982 May; 30(22):1875-83. PubMed ID: 7109826
[TBL] [Abstract][Full Text] [Related]
18. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
[TBL] [Abstract][Full Text] [Related]
19. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
20. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand.
Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ
J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
